The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.
Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
